{"version":"1.0","type":"link","title":"Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.","author_name":"Xiao Z 외","author_url":"https://prs-insight.online/author/Xiao%20Z","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/92222","thumbnail_width":1200,"thumbnail_height":630}